Clinical trial NCT00590720: A Phase 2A Study to Evaluate the Safety and Effect on Exercise Challenge Testing of MEDI-528 in Adults With Asthma
Official title: A Phase 2A, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety and Effect on Exercise Challenge Testing of Multiple Fixed Subcutaneous Doses of MEDI-528, A Humanized Anti-Interleukin-9 Monoclonal Antibody, in Adults With Stable Asthma and Exercise-Induced Bronchoconstriction
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: Asthma
Keywords: Asthma
Bronchitis
Lead sponsor: MedImmune LLC
Sponsor class: INDUSTRY
First posted: 2008-01-11
Enrollment: 11
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The main objective of this study is to evaluate the safety and tolerability of multiple fixed doses of MEDI-528 in adult patients with stable asthma and exercise-induced bronchoconstriction (EIB).

Detailed description: The primary objective of this study is to evaluate the safety and tolerability of multiple fixed escalating SC doses of MEDI-528 in adult patients with stable asthma and exercise-induced bronchoconstriction (EIB).

Eligibility criteria: Inclusion Criteria:

Patients must meet all of the following criteria:

* Male or female adults, age 18 through 50 years at the time of screening;
* Weight 50-100 kg and body mass index ≤ 35;
* Written informed consent obtained from the patient prior to receipt of any study medication or beginning study procedures;
* Documented clinical history of asthma and receiving stable treatment for ≥ 1 month prior to Study Day 0;
* Airway hyperresponsiveness (AHR) on methacholine inhalation challenge testing at screening (or a documented history within the past 6 months), with provoking concentration of methacholine to cause a 20% fall in FEV1(subscript) (PC20) ≤ 8 mg/mL (Crapo, 2000);
* Exercise-induced bronchoconstriction (EIB) with a decrease in FEV1 (subscript) of ≥ 15% from pre-exercise challenge testing level at screening;
* Able to provide spirometry readings that meet American Thoracic Society (ATS) and European Respiratory Society (ERS) standards (Miller, 2005);
* Women of childbearing potential, unless surgically sterile or at least 1 year post-menopausal, must use two effective methods of avoiding pregnancy (including oral, transdermal, or implanted contraceptives, intrauterine device, female condom, spermicide, diaphragm, cervical cap, abstinence, contraceptive foam, or use of a condom by the sexual partner or sterile sexual partner) from screening through Study Day 0, and must agree to continue using such precautions through Study Day 150. Cessation of birth control after this point should be discussed with a responsible physician. Men, unless surgically sterile, must likewise use an effective method of birth control (condom with spermicide) and must agree to continue using such precautions from screening through Study Day 150;
* Able to complete the study period, including follow-up period, of up to approximately 150 days; and
* Willing to forego other forms of experimental treatment and study procedures during the study and for 30 days after the follow-up period is completed.

Exclusion Criteria:

Patients must have none of the following criteria:

* Receipt of MEDI-528 in any previous clinical study;
* History of allergy or reaction to any component of the study drug formulation;
* Lung disease other than asthma (eg, chronic obstructive pulmonary disease, cystic fibrosis);
* Forced expiratory volume in 1 second (FEV1-subscript) \< 70% of predicted values at screening;
* Use of systemic immunosuppressive drugs including systemic corticosteroids, ICS with doses \> 800 μg/day budesonide (or another ICS of equivalent dose), long-acting β2 agonists, cromolyn sodium, nedocromil sodium, leukotriene receptor antagonists, theophylline, or omalizumab from screening through Study Day 150;
* Current use of any β-adrenergic antagonist (eg, propranolol);
* Any disease or illness, other than asthma, that is likely to require the use of systemic corticosteroids during the study period;
* Acute illnesses or evidence of significant active infection, such as fever ≥ 38.0°C (100.5°F) from screening through Study Day 0;
* Current allergy vaccination therapy (desensitization immunotherapy);
* Receipt of any investigational drug therapy within 30 days or any biologic(s) within 5 half-lives of the agent prior to screening;
* Pregnancy (women of child bearing potential, unless surgically sterile or at least 1 year postmenopausal, must have a negative serum and urine pregnancy test at screening before methacholine inhalation challenge testing and a negative urine pregnancy test prior to study drug administration on Study Day 0);
* Breastfeeding or lactating woman;
* Evidence of infection with hepatitis B or C virus or HIV-1 or HIV-2, or active infection with hepatitis A; must have negative HIV-1, HIV-2, hepatitis A, B, and C tests at screening;
* History of cancer other than basal cell carcinoma of the skin or cervical carcinoma-in-situ treated with apparent success with curative therapy more than 1 year prior to Study Day 0;
* History of primary immunodeficiency
* History of pancreatitis or currently active gastroduodenal ulcer;
* Current use of tobacco products or a history of use of tobacco products of more than one cigarette per month or equivalent within 1 year prior to randomization or history of smoking of ≥ 10 pack-years;
* History of life-long urinary retention;
* History of anaphylaxis (defined as immediate life-threatening event requiring medical invention);
* Elective surgery planned from screening through Study Day 150;
* Clinically significant abnormality, as determined by the investigator, on 12-lead ECG or chest radiograph at screening;
* History of any disease, evidence of any current disease (other than asthma), any finding upon physical examination, or any laboratory abnormality, that, in the opinion of the investigator or medical monitor, may compromise the safety of the patient in the study or confound the analysis of the study; or
* Any employee of the research site who is involved with the conduct of the study.

Primary outcomes:
measure: Incidence of Adverse Events
timeFrame: Days 0 - 150
measure: Incidence of Serious Adverse Events
timeFrame: Days 0 - 150
Secondary outcomes:
measure: Incidence of Anti-drug Antibodies (ADA) to MEDI-528
timeFrame: Days 0, 28, 56, 119, and 150
measure: Absolute Maximum Change in Forced Expiratory Volume in 1 Second (FEV1)
timeFrame: Day 28 (15 minutes prior to exercise and 5, 10, 15, 20, and 30 minutes after exercise)
measure: Absolute Maximum Change in Forced Expiratory Volume in 1 Second (FEV1)
timeFrame: Day 56 (15 minutes prior to exercise and 5, 10, 15, 20, and 30 minutes after exercise)
measure: Absolute Maximum Change in Forced Expiratory Volume in 1 Second (FEV1)
timeFrame: Day 150 (15 minutes prior to exercise and 5, 10, 15, 20, and 30 minutes after exercise)
measure: Percent Maximum Change in Forced Expiratory Volume in 1 Second (FEV1)
timeFrame: Day 28 (15 minutes prior to exercise and 5, 10, 15, 20, and 30 minutes after exercise)
measure: Percent Maximum Change in Forced Expiratory Volume in 1 Second (FEV1)
timeFrame: Day 56 (15 minutes prior to exercise and 5, 10, 15, 20, and 30 minutes after exercise)
measure: Percent Maximum Change in Forced Expiratory Volume in 1 Second (FEV1)
timeFrame: Day 150 (15 minutes prior to exercise and 5, 10, 15, 20, and 30 minutes after exercise)
measure: Area Under the Curve (AUC) of Forced Expiratory Volume in 1 Second (FEV1)
timeFrame: Day 28 (15 minutes prior to exercise and 5, 10, 15, 20, and 30 minutes after exercise)
measure: Area Under the Curve (AUC) of Forced Expiratory Volume in 1 Second (FEV1)
timeFrame: Day 56 (15 minutes prior to exercise and 5, 10, 15, 20, and 30 minutes after exercise)
measure: Area Under the Curve (AUC) of Forced Expiratory Volume in 1 Second (FEV1)
timeFrame: Day 150 (15 minutes prior to exercise and 5, 10, 15, 20, and 30 minutes after exercise)
measure: Time to Return in Minutes to 90 Percent of Baseline Forced Expiratory Volume in 1 Second (FEV1)
timeFrame: Day 28 (15 minutes prior to exercise and 5, 10, 15, 20, and 30 minutes after exercise)
measure: Time to Return in Minutes to 90 Percent of Baseline Forced Expiratory Volume in 1 Second (FEV1)
timeFrame: Day 56 (15 minutes prior to exercise and 5, 10, 15, 20, and 30 minutes after exercise)
measure: Time to Return in Minutes to 90 Percent of Baseline Forced Expiratory Volume in 1 Second (FEV1)
timeFrame: Day 150 (15 minutes prior to exercise and 5, 10, 15, 20, and 30 minutes after exercise)
measure: Mean Trough Concentration (Cmin)
timeFrame: Days 0, 3, 7, 10, 14, 17, 21, 24, 28, 32, 37, 42, 56, 70, 84, 119, and 150
measure: Mean Trough Concentration at Last Measurable Time Point (Cmin_last)
timeFrame: Days 0, 3, 7, 10, 14, 17, 21, 24, 28, 32, 37, 42, 56, 70, 84, 119, and 150
measure: Half-life (T1/2)
timeFrame: Days 0, 3, 7, 10, 14, 17, 21, 24, 28, 32, 37, 42, 56, 70, 84, 119, and 150
measure: Accumulation Index
timeFrame: Days 0 and 24
Other outcomes:
Locations:
city: San Diego
country: United States
facility: Institute of Healthcare Assessment, Inc
state: California
city: Denver
country: United States
facility: National Jewish Medical and Research Center
state: Colorado
city: Waterbury
country: United States
facility: Waterbury Pulmonary Associates
state: Connecticut
city: Tampa
country: United States
facility: Univ. of South Florida, Asthma, Allergy & Immunology Clinical Research Unit
state: Florida
city: Normal
country: United States
facility: Sneeze,Wheeze & Itch Associates, LLC
state: Illinois
city: No. Dartmouth
country: United States
facility: Northeast Medical Research Associates, Inc
state: Massachusetts
city: St. Louis
country: United States
facility: The Clinical Research Center, LLC
state: Missouri
city: Omaha
country: United States
facility: Creighton University
state: Nebraska
city: Cincinnati
country: United States
facility: Bernstein Clinical Research Center
state: Ohio
city: Calgary
country: Canada
facility: Calgary COPD & Asthma Program
state: Alberta
city: Toronto
country: Canada
facility: UHN- Toronto Western Hospital
state: Ontario
city: Quebec City
country: Canada
facility: Centre de Recherche Appliquee en Allergie de Quebec
state: Quebec
Study officials:
affiliation: MedImmune LLC
name: Joseph Parker, M.D.
role: STUDY_DIRECTOR
References:
citation: Parker JM, Oh CK, LaForce C, Miller SD, Pearlman DS, Le C, Robbie GJ, White WI, White B, Molfino NA; MEDI-528 Clinical Trials Group. Safety profile and clinical activity of multiple subcutaneous doses of MEDI-528, a humanized anti-interleukin-9 monoclonal antibody, in two randomized phase 2a studies in subjects with asthma. BMC Pulm Med. 2011 Feb 28;11:14. doi: 10.1186/1471-2466-11-14.